Branded Generics

Our Branded Generics division develops, manufactures and markets products that are the therapeutic equivalent to their brand name counterparts. IMS Health, which began tracking and reporting on branded generics in 2002, defines the category as including prescription "products that are either novel dosage forms of off-patent products produced by a manufacturer that is not the originator of the molecule, or a molecule copy of an off-patent product with a trade name." This definition is used by both the FDA and the United Kingdom's National Health Service (NHS).

Our portfolio for this business includes products we have internally developed, products we have licensed, and products we distribute for third parties. Our branded generics cover a broad range of treatments including antibiotics, antifungal medications, and diabetic therapies among many others. Valeant's branded generics business comprises approximately 35% of its product portfolio and is primarily focused in Central Europe and Latin America.

Please view our Product Table for a list of Valeant's branded generic products.